Zydus receives final approval from USFDA for Ketoconazole Shampoo, 2%

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Ketoconazole Shampoo, 2% (USRLD: Nizoral® Shampoo, 2%).

Ketoconazole shampoo is an antifungal medication used to treat dandruff, fungal infections, and other skin conditions. Ketoconazole shampoo will be produced at the Group's topical manufacturing site at Changodar, Ahmedabad.

Ketoconazole shampoo had annual sales of USD 68.89 mn in the United States (IQVIA MAT January 2025).

The group now has 418 approvals and has so far filed 483* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 901.15 as compared to the previous close of Rs. 906.95. The total number of shares traded during the day was 32058 in over 2253 trades.

The stock hit an intraday high of Rs. 917.25 and intraday low of 896.30. The net turnover during the day was Rs. 29136848.00.

(*As on 31st December, 2024.)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals USFDA Approval KetoconazoleShampoo